Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 7/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | DHFR | P00374 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | EDNRA | P25101 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | HTR6 | P50406 | 4/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1576354 | 0.84 | ALDH1A1 (0.57) | SMN1; SMN2CYP2C19TSHRCYP2C9ALDH1A1 | |
| SCHEMBL18843940 | 0.84 | SCN9A (0.54) | SMN1; SMN2CYP2C19LMNAALDH1A1KDM4E | |
| SCHEMBL1094173 | 0.83 | POLB (0.55) | SMN1; SMN2LMNAALDH1A1KDM4E | |
| SCHEMBL2180207 | 0.81 | CA2 (0.53) | ALDH1A1KDM4EKMT2AEDNRATDP1 | |
| SCHEMBL28319395 | 0.81 | SLC22A12 (0.45) | SMN1; SMN2LMNAKDM4E | |
| Sulfapyridine SCHEMBL44219 | 0.79 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAAURKADHFRTSHR | |
| Sulfapyridine SCHEMBL29438089 | 0.79 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAAURKADHFRTSHR | |
| SCHEMBL24125201 | 0.78 | KDM4E (0.44) | SMN1; SMN2ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL152522 | 0.77 | SMN1; SMN2 (0.65) | SMN1; SMN2CYP2C19LMNAAURKADHFR | |
| SCHEMBL2350284 | 0.77 | CYP2C19 (0.68) | SMN1; SMN2CYP2C19LMNAAURKADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021257544-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-12-23 | — | — | WO | disclosed |
| US-20130022629-A1 | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2013-01-24 | — | — | US | disclosed |
| US-20130022629-A1 | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2013-01-24 | — | — | US | disclosed |
| EP-1527051-B1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011082400-A2 | MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011082400-A2 | MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-07-07 | — | — | WO | disclosed |
| US-6030976-A | SELECTIVE AFFINITY TO 5HT-6 RECEPTORS; CENTRAL NERVOUS SYSTEM DISORDERS; ALZHEIMER'S DISEASE, PSYCHOSES, SCHIZOPHRENIA, MANIC DEPRESSIONS, MEMORY DISORDERS, PARKINSON'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS AND HUNTINGTON'S DISEASE | HOFFMAN-LA ROCHE INC. (US) | 2000-02-29 | — | — | US | disclosed |
| US-5998665-A | THERAPY FOR NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-12-07 | — | — | US | disclosed |
| US-5939451-A | INDOL-4-YL-BENZENESULFONAMIDES AS ACTIVE MATERIAL TREATING MALARIA, BACTERIAL INFECTION, NEUROLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-08-17 | — | — | US | disclosed |
| US-5932599-A | 4-AMINO-N-(PYRIDINYL-4-YL)-BENZENESULFONAMIDES AS ACTIVE MATERIAL TREATING MALARIA, BACTERIAL INFECTION, NEUROLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130022629-A1 | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof | CD274, PDCD1LG2, PDCD1 | SMN1; SMN2 4661/4885CYP2C19 2798/4885LMNA 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.